ACPH.BR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Stats
Today's Volume	761 376
Average Volume	402 314
Market Cap	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.396
ATR14	$0 (0.00%)

Acacia Pharma Group PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acacia Pharma Group PLC Financials

Annual	2021
Revenue:	$1.16M
Gross Profit:	$868 000 (74.63 %)
EPS:	$-0.840

FY	2021
Revenue:	$1.16M
Gross Profit:	$868 000 (74.63 %)
EPS:	$-0.840

FY	2020
Revenue:	$211 000
Gross Profit:	$182 000 (86.26 %)
EPS:	$-0.624

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.430

Financial Reports:

No articles found.

Acacia Pharma Group PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acacia Pharma Group PLC

Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.